Company / Depreciation & Amortization
GeneDx Holdings Corp. Depreciation & Amortization History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$9.6M
FY2025
5-year range
$7.9M / $50.0M
FY2021-FY2025
Trend
+21.5%
vs FY2024
Sector context
#113 of 135
Health Care
What the data says
GeneDx Holdings Corp.'s depreciation & amortization of $10M is lower than 84% of companies in the Health Care sector (FY2025). Depreciation & Amortization returned to growth in FY2025 after 2 years of decline, reaching $10M.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of -3.9%.
Improved from $20M to $10M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -42.3%
- 5-Year CAGR
- -3.9%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 135This company $9.6M Sector average $334.5M
▼
-97.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.9%, indicating a declining trend.
- In FY2025, depreciation & amortization increased 21.5% year-over-year.
- Ranks #113 out of 135 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.6M | +21.5% |
| FY2024 | $7.9M | -59.9% |
| FY2023 | $19.7M | -60.6% |
| FY2022 | $50.0M | +129.3% |
| FY2021 | $21.8M | +85.8% |
| FY2020 | $11.7M | +83.1% |
| FY2019 | $6.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026